XML 48 R38.htm IDEA: XBRL DOCUMENT v3.8.0.1

Segments (Tables)

3 Months Ended

Mar. 31, 2018

Segment information

a. Segment information:

		North America								Europe								Growth Markets
		Three months ended March 31,								Three months ended March 31,								Three months ended March 31,
		2018				2017				2018				2017				2018				2017
		(U.S. $ in millions)								(U.S. $ in millions)								(U.S. $ in millions)
Revenues		$	2,531			$	3,240			$	1,442			$	1,341			$	750			$	718
Gross profit			1,432				2,080				797				734				313				292
R&D expenses			188				267				73				106				24				47
S&M expenses			305				441				255				279				134				158
G&A expenses			126				139				91				79				41				48
Other income			(102	)			(73	)			1				2				(8	)			(1	)
Segment profit		$	915			$	1,306			$	377			$	268			$	122			$	40

		Three months ended March 31,
		2018				2017
		(U.S.$ in millions)
North America profit		$	915			$	1,306
Europe profit			377				268
Growth Markets profit			122				40
Total segment profit			1,414				1,614
Profit of other activities			21				7
			1,435				1,621
Amounts not allocated to segments:
Amortization			310				320
Other asset impairments, restructuring and other items			707				240
Goodwill impairment			180				—
Gain on divestitures, net of divestitures related costs			(93	)			—
Inventory step-up			—				64
Other R&D expenses			22				—
Costs related to regulatory actions taken in facilities			1				34
Legal settlements and loss contingencies			(1,278	)			20
Other unallocated amounts			61				48
Consolidated operating income			1,525				895
Financial expenses, net			271				207
Consolidated income before income taxes		$	1,254			$	688

Schedule of Net Sales by Product Line

b. Segment revenues by major products and activities:

The following tables present revenues by major products and activities for the three months ended March 31, 2018 and 2017:

		Three months ended March 31,
		2018				2017
		(U.S.$ in millions)
North America segment
Generic products		$	1,088			$	1,415
COPAXONE			476				797
BENDEKA / TREANDA			181				156
ProAir			130				121
QVAR			107				84
AUSTEDO			30				—
Distribution			331				295
		Three months ended March 31,
		2018				2017
		(U.S.$ in millions)
Europe segment
Generic products		$	997			$	850
COPAXONE			153				152
Respiratory products			113				84
		Three months ended March 31,
		2018				2017
		(U.S.$ in millions)
Growth Markets segment
Generic products		$	488			$	486
COPAXONE			16				21
Distribution			153				125

X

- Definition

A schedule of net sales by major product line.

+ References

No definition available.

+ Details

Name:	teva_SalesByProductLineTableTextBlock
Namespace Prefix:	teva_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

Name:	us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration